Second Sight Medical Products Inc. (EYES)

0.77
0.02 2.03
NASDAQ : Health Technology
Prev Close 0.79
Open 0.78
Day Low/High 0.76 / 0.79
52 Wk Low/High 0.64 / 1.20
Volume 137.88K
Avg Volume 208.00K
Exchange NASDAQ
Shares Outstanding 124.60M
Market Cap 102.16M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Looking at What's New in the Portfolio

Looking at What's New in the Portfolio

Holdings in shipping, oil and a vision-restoration process.

Everybody's Doing It: 5 Stocks Under $10 That I Like

Everybody's Doing It: 5 Stocks Under $10 That I Like

These have positive momentum and good growth.

Second Sight Soars on News While Navios Maritime Looks to Steam Ahead

The two companies are wholly different, though both give investors reasons for optimism.

Second Sight Should See Its Way Forward

Timing is key in investing and EYES shares should pop if a rights offering proves successful for the cash-needy company.

Just a Routine Market Pullback

This sort of action is needed periodically.

Market Is Brushing Off the Brussels Attack

I'm checking out EYES, MITK, ORBC and gold in the early going.

Falling Into a Trading-Range Market

Breadth is running about 2 to 1 negative, and there is weakness in the large-cap FATMAN names.

4 Low-Priced Small-Caps to Put on Your Radar

4 Low-Priced Small-Caps to Put on Your Radar

Now is not the time to buy them, but they have the potential for big moves.

Holiday Market Surge Has a Familiar Jingle

But it's still not a Santa Claus rally.

It's Hard to Party in a Contrary Market

It's Hard to Party in a Contrary Market

It's unclear whether the market can get into the holiday spirit and produce some upside as we roll into 2017.

'Sell the News' Isn't Dead, Just Delayed

With the Fed out of the way, look for traders to be active into the end of the year.

The Fed's Rate Decision Looms Larger

The Fed's Rate Decision Looms Larger

The Fed will be the catalyst for the next market move and, given the technical picture, that could easily be lower.

Market Has a Mood Swing to the Upside

Gloom is gone as likelihood of Fed rate hike fades.

Yawning All the Way to the Fed Decision

We have a few more days of this slow trading, and it is unlikely to change much.

The EYES Have It: Research Reveals 3 Stocks to Buy

Want an antidote for volatility? Do your homework.

When and Where Will We Find a Bottom?

When and Where Will We Find a Bottom?

Market is following textbook corrective action.

Is This the Calm Before Another Storm?

Sedate trading is welcome, but there hasn't been an all-clear signal.

Building a Sweet 16 Portfolio, Part 2

Building a Sweet 16 Portfolio, Part 2

A little of this, a little of that to create a nice yield.

Building a Sweet 16 Portfolio, Part 1

Selection of stocks is tailor made for investor, given market parameters.

Market's Not in the Mood to Move

Market's Not in the Mood to Move

Attention turns to earnings and away from Greece, Fed.

Market Still Isn't Convinced About Greece

Market Still Isn't Convinced About Greece

Lots of gains, but we ended up closing where we opened.

Where Have All the V-Shaped Moves Gone?

Where Have All the V-Shaped Moves Gone?

Market has been lacking aggressive upside momentum.

Optimism Creeps Back Into the Market

Traders feel Greek disaster averted -- for now.

How Quickly Can the Market Bounce Back?

Today's selling was steady; question is how long it will persist.

Market Advances by Playing Small Ball

Not too exciting, but bulls keep chugging along.

Market Closes Back Where It Started

Greece provides good news, but bulk of action wasn't intraday.

An Eye for EYES, and Here Are the Whys

Second Sight Medical Products is producing a promising vision restoration device, with more in the pipeline.

The Trend Says It's a Very Friendly Market

The Trend Says It's a Very Friendly Market

You can find flaws with it, but there isn't money to be gained by fighting its strength.